Increased levels of FGF-2 in SCLC patients’ blood were correlated with higher angiogenesis and worse clinical outcomes; in the end, it has been reported that FGF-2 stimulates SCLC growth and chemotherapeutic drug resistance [30]. The gene discussed is FGF2; the disease is small cell lung carcinoma.